事件 RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (摘要) 会议：American…Xu chunjieApril 9, 2025
RAG-01 Presentation事件 First-in-human study of RAG-01, a novel small activating RNA therapeutic in BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC) patients(摘要) 会议：40th…Xu chunjieMarch 24, 2025
RAG-01 Presentation事件 Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment (摘要) 会议:…ractigenOctober 11, 2024
事件 RAG-17: A Promising Novel Gene Silencing Therapy for SOD1-ALS Preliminary Safety and Efficacy Data from a First-in-Human Trial (摘要) 会议：Society…Xu chunjieOctober 7, 2024
事件 Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (海报) 会议：2024…ractigenMarch 21, 2024
事件 SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (海报) 会议:…EnvisionNovember 2, 2023
事件 Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (海报) 会议:…EnvisionNovember 2, 2023
RAG-01 Presentation事件 Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (摘要) 会议:…EnvisionJune 7, 2023
RAG-17 Presentation事件 siRNA-ACO is a convenient phosphoramidite-based conjugate that enables RNAi in the CNS via local administration with superior efficacy in the treatment of ALS rodent models (海报) 会议:…EnvisionMay 12, 2023
RAG-17 Presentation事件 Local administration of a novel siRNA conjugate (siRNA-ACO) into the CNS extends survival and improves motor function in the SOD1G93A mouse model for ALS (海报) 会议:…EnvisionMarch 10, 2023
